$PTHS

Pelthos (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics reported Q2 2026 net product revenue of $15.4M, up 45% from Q1. ZELSUVMI prescriptions rose 48% to 11,925 units. Adjusted EBITDA loss narrowed to $5.7M. The company has $24.2M in cash and plans to launch XEPI and Xeglyze in 2027. COGS included a $900K inventory write-off, and SG&A had a $5.3M milestone payment.

Original reporting
Published Aug 20, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pelthos (PTHS) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PTHSNeutralHigh
01

Why it matters

The earnings beat provides a fresh data point for valuation models, influencing short-term trading decisions and sector sentiment.

02

Market read

First-report earnings data for a small-cap biotech, offering actionable insight for traders.

03

What to watch

Potential future PBM contract expansions and upcoming product launches (XEPI, Xeglyze) could materially improve long-term outlook.

Relevance 7/10Novelty 8/10Timing: today

Background

Pelthos Therapeutics reported its Q2 2026 financial results, highlighting rapid growth in its ZELSUVMI product line and upcoming launches.

Company-level read

Ticker impact

$PTHSNeutralHigh confidence
Context

Q2 2026 earnings release shows 45% sequential revenue growth and narrowed losses, providing fresh valuation data.

Expected impact

Potential short-term price rally on revenue beat, followed by volatility due to ongoing losses.

Evidence & confidence

Strong top-line growth is a positive catalyst, but negative EBITDA and cash constraints limit upside.

Market effects

Positive signal for niche dermatology biotech sector, may boost peer valuations.

Limited to US biotech investors; no broader regional effect.

Minor global impact; primarily relevant to US small-cap biotech market.

Counterpoint

Despite revenue growth, persistent losses and cash burn could lead to a sell-off if guidance remains weak.

Key entities

  • Pelthos Therapeutics

    Biopharmaceutical company developing topical treatments.

  • Scott Plesha

    Chief Executive Officer of Pelthos.

Related articles

$PTHSMed

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Pelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescr

$GBCIMed

Glacier Bancorp Inc (GBCI) (Q3 2026) Earnings Call Highlights: Record $105 Million Profit

Glacier Bancorp (GBCI) reported Q3 2026 record profit of $105M. Loan growth expected to slow, deposit costs may rise with Fed rate hikes. Non-interest expense was $190.8M, higher than guidance. CEO considers share buybacks or special dividends. Margin expansion expected through 2027, with net interest margin potentially reaching 4.5%. Deposit growth was strong, with noninterest-bearing deposits up 15% annualized.

$INFYHighAI 8/10

Infosys Ltd (INFY) (Q2 2027) Earnings Call Highlights: AI Revenue Surges 29%

Infosys reported Q2 2027 revenue growth of 1.5% YoY and 1.2% sequentially, below expectations. AI revenue surged 29% QoQ. The company revised full-year guidance to 1-2% growth due to pricing pressure, cautious client spending, and softness in high-tech and retail sectors. CEO Salil Parekh expressed confidence in organic growth recovery for FY28, citing a $2B+ mega deal and strong AI traction.

$SLGMed

SL Green Realty Corp (SLG) (Q3 2026) Earnings Call Highlights: 95% Leased Occupancy

SL Green Realty Corp (SLG) reported 95% leased occupancy and raised guidance. The company has a leasing pipeline exceeding 1.3M sq ft, with mark-to-market above 20%. Higher interest rates impacted guidance by $0.25, with $0.05 from fee income and the rest from interest expense. Cap rates are expected to stay around 5-6%, with strong rent growth. Development opportunities are modeled at $240-$270 per sq ft.

$YARIYMed

Yara International ASA (YARIY) (Q3 2026) Earnings Call Highlights: EBITDA Slips to $675

Yara International ASA (YARIY) reported Q3 2026 EBITDA of $675 million, down from $804 million YoY, due to higher European gas costs and lower volumes. The company curtailed 270,000 tons of ammonia production and faced demand slowdowns, particularly in Latin America. Management discussed gas cost impacts, production curtailments, and market demand trends during the earnings call.